The Anxiety and Depression Association of America is pleased to announce an award to an early career investigator for the best original research paper on neurobiology, psychopharmacology, psychosocial treatments, or experimental psychopathology of anxiety disorders and depression.
Award Criteria and Eligibility
- The award is restricted to investigators who have completed their terminal degree and are currently at a rank of assistant professor or below.
- Individuals who are working to complete their degree are not eligible.
- Applicants must be the first or senior author on the submitted paper, which must be original research on anxiety disorders, depression, and comorbid related disorders, focusing on neurobiology, psychosocial treatments, or experimental psychopathology.
- The paper may not be published or in press elsewhere.
- Applicants must be members of ADAA, but we welcome new members, so interested nonmembers should feel free to join and then submit.
- Complimentary registration to the ADAA Annual Conference
- Recognition at the Opening Session
- $500 award
- Rapid publication in Depression and Anxiety
- Assignment of a mentor from the ADAA Scientific Council
- Invitation to participate in the 2017 award selection committee and get involved in other activities of the organization
Submission Preparation and Review
- Submissions should be sent to ADAA, in English, following the author guidelines for Depression and Anxiety. Word limits for this award are extended to 4,000 for original research.
- Download the application to your computer.
- Type in all the fields, including typing your name in the "Applicant Signature" field.
- Save the document; rename it 2016_Awards_Klein_[YourLastName}; and e-mail as an attachment along with a copy o fyour manuscript.
- Manuscripts will be peer-reviewed by a committee of researchers. Applicants cannot submit this paper to other journals during the review period.
Contact ADAA with questions.
About Donald F. Klein
This award is named for Donald F. Klein, MD, who revolutionized psychiatric thinking through his discovery in the early 1960s that imipramine, a recently developed psychotropic medication, was effective in blocking panic attacks. Dr. Klein’s early contribution to the development of the DSM in large part gave birth to the modern branch of medical science dealing with the classification of disease of anxiety disorders. His early findings also heralded in the era of childhood anxiety disorders as biochemical disorders when he discovered that imipramine blocked childhood separation anxiety disorders.
In later years, Dr. Klein developed a compelling evolutionary-based hypothesis accounting for the etiology of panic disorders, which he terms “the false suffocation alarm theory of panic disorders.” His work remains relevant and topical to the present. Dr. Klein was the recipient of the 2005 ADAA Lifetime Achievement Award.
The Donald F. Klein Early Career Investigator Award is supported by Depression and Anxiety, the official journal of ADAA, published by Wiley-Blackwell, the scientific, technical, medical, and scholarly business of John Wiley & Sons, Inc.